Live Breaking News & Updates on Nefecon

Stay updated with breaking news from Nefecon. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Budesonide Reduces eGFR Decline, Effect Could Prevent Clinical Events in IgA Nephropathy

Data for a pair of studies presented at Kidney Week 2023 provide an overview of the effects of eGFR and how this might translate to potential long-term benefit in patients IgA nephropathy. ....

United States , Richard Lafayette , Jonathan Barratt , University Of Leicester , Stanford Glomerular Disease Center , Alnylam Pharmaceuticals , American Society Of Nephrology Kidney Week , American Society , Nephrology Kidney Week , Igard Study , Kidney Week , Mayer Professor , Renal Medicine , Leicester General , Calliditas Therapeutics , Travere Therapeutics , Chinook Therapeutics , Iga Nephropathy Treated , Year Nefigard Phase , Paper Presented , Nefigard Two Year , Slope Predicts Long Term Clinical Benefit , Real World Iga Nephropathy , Priority Review , Asn Kidney Week , Iga Nephropathy ,

#VisualAbstract: Budesonide may be effective for slowing renal function decline in patients with IgA nephropathy

1. Reduction in time-weighted glomerular filtration rate (GFR) decline was significantly greater in Nefecon versus placebo. 2. Majority of adverse events were mild-to-moderate in nature with no treatment-related deaths. Evidence Rating Level: 1 (Excellent) Study Rundown: IgA nephropathy is a chronic immune-mediated kidney disease with marked proteinuria. Nefecon, a novel, targeted-release form of budesonide, is designed ....

Minute Medicine Inc , Rating Level , Intensive Supportive Care , Between Sept , Iga Nephropathy , Kidney Failure ,

Budesonide may be effective for slowing renal function decline in patients with IgA nephropathy

1. Reduction in time-weighted glomerular filtration rate (GFR) decline was significantly greater in Nefecon versus placebo. 2. Majority of adverse events were mild-to-moderate in nature with no treatment-related deaths. Evidence Rating Level: 1 (Excellent) Study Rundown: IgA nephropathy is a chronic immune-mediated kidney disease with marked proteinuria. Nefecon, a novel, targeted-release form of budesonide, is ....

Rating Level , Intensive Supportive Care , Between Sept , Iga Nephropathy , Kidney Failure , Primary Iga Nephropathy , Chronic Disease ,

New Biomarker, Subgroup Analyses of Phase 3 NefIgArd Trial for Budesonide

Positive findings from NefIgArd demonstrated budesonide’s ability to modulate the intestinal immune network responsible for IgA production. ....

Jonathan Barratt , Richard Phillipson , International Symposium On Iga Nephropathy Iigann Tokyo , Drug Administration , International Symposium On Ig , International Symposium On Iga Nephropathy , George Clinical , Calliditas Therapeutics , Cc Motif Chemokine Ligand , International Symposium , Chief Medical Officer , Prescription Drug User Fee Act , Iga Nephropathy , Mayer Professor , Renal Medicine , Calliditas Presents Data , Nefigard Phase , Calliditas Therapeutics Accelerated Approval , Reduce Proteinuria , Patients With Primary Iga , Igard Trial Evaluating Nefecon , Immunoglobulina Nephropathy ,

Calliditas Therapeutics: China CDE/NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA Nephropathy

STOCKHOLM, Dec. 30, 2022 /PRNewswire/ Calliditas Therapeutics AB (publ) ("Calliditas") partner Everest Medicines (HKEX 1952.HK) today announced that the Center for Drug Evaluation (CDE) of ....

United States , Marie Galay , Rogers Luo , Exchange Commission , China National Medical Products Administration , European Commission , European Union Member States , Everest Medicines , Drug Evaluation , Priority Review , New Drug Application , Nasdaq Stockholm , American Depositary Shares , Nasdaq Global Select Market , Private Securities Litigation Reform Act ,